Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | GBA1 | P04062 | 1/20 | 0.40 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 5/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1063890 | 1.00 | ALDH1A1 (0.42) | ALDH1A1KDM4EGBA1MCHR1RAB9A | |
| SCHEMBL23515097 | 0.83 | ALDH1A1 (0.40) | ALDH1A1KDM4EGBA1MCHR1RAB9A | |
| SCHEMBL17674283 | 0.83 | KDM4E (0.42) | ALDH1A1KDM4EGBA1MCHR1RAB9A | |
| SCHEMBL7410889 | 0.82 | ESR1 (0.45) | ALDH1A1RAB9ANPC1CA2 | |
| SCHEMBL20168330 | 0.82 | HDAC1 (0.50) | ALDH1A1KDM4EGBA1MCHR1RAB9A | |
| SCHEMBL3060324 | 0.81 | ALDH1A1 (0.43) | ALDH1A1KDM4ERAB9ANPC1MAOB | |
| SCHEMBL11016027 | 0.81 | ALDH1A1 (0.52) | ALDH1A1MCHR1RAB9ANPC1MAPT | |
| SCHEMBL11386635 | 0.79 | ALDH1A1 (0.42) | ALDH1A1RAB9ANPC1CA2TSHR | |
| SCHEMBL25302669 | 0.79 | ALDH1A1 (0.43) | ALDH1A1KDM4ERAB9ANPC1SIRT2 | |
| SCHEMBL23497624 | 0.79 | ALDH1A1 (0.36) | ALDH1A1KDM4EGBA1MCHR1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240360133-A1 | FUSED TRICYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF IN MEDICINE | JIANGSU HENGRUI PHARMACEUTICALS CO., LTD. (CN) | 2024-10-31 | — | — | US | disclosed |
| EP-4253387-A1 | FUSED TRICYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF IN MEDICINE | Jiangsu Hengrui Pharmaceuticals Co., Ltd. (CN) | 2023-10-04 | — | — | EP | disclosed |
| EP-4073062-A1 | FUNCTIONALIZED HETEROCYCLIC COMPOUNDS AS MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) | Ryvu Therapeutics S.A. (PL) | 2022-10-19 | — | — | EP | disclosed |
| EP-4073063-A1 | HETEROCYCLIC COMPOUNDS AS MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) | Ryvu Therapeutics S.A. (PL) | 2022-10-19 | — | — | EP | disclosed |
| WO-2022111636-A1 | FUSED TRICYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF IN MEDICINE | 江苏恒瑞医药股份有限公司 | 2022-06-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240360133-A1 | FUSED TRICYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF IN MEDICINE | TLR7, TLR8, TLR9 | ALDH1A1 2214/4885KDM4E 2622/4885GBA1 418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.